CA2621866A1 - Stable solid formulation of sertindole - Google Patents

Stable solid formulation of sertindole Download PDF

Info

Publication number: CA2621866A1
Authority: CA; Canada
Prior art keywords: pharmaceutical composition; solid pharmaceutical; sertindole; coating layer; protective agent
Prior art date: 2005-09-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002621866A

Other languages

English (en)

French (fr)

Inventor

Flemming Enok Olsen

Anne Ravnholdt Christensen

Ken Liljegren

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

H Lundbeck AS

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-08

Filing date

2006-09-06

Publication date

2007-06-14

2006-09-06 Application filed by Individual filed Critical Individual

2007-06-14 Publication of CA2621866A1 publication Critical patent/CA2621866A1/en

Status Abandoned legal-status Critical Current

Links

GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 title claims abstract description 62
229960000652 sertindole Drugs 0.000 title claims abstract description 62
239000000203 mixture Substances 0.000 title claims description 40
239000007787 solid Substances 0.000 title claims description 40
238000009472 formulation Methods 0.000 title description 3
UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims abstract description 92
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 45
239000011247 coating layer Substances 0.000 claims abstract description 41
239000003223 protective agent Substances 0.000 claims abstract description 37
230000005855 radiation Effects 0.000 claims abstract description 29
JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims abstract description 9
238000002360 preparation method Methods 0.000 claims abstract description 9
201000000980 schizophrenia Diseases 0.000 claims abstract description 6
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 34
239000010410 layer Substances 0.000 claims description 27
238000000576 coating method Methods 0.000 claims description 26
239000002775 capsule Substances 0.000 claims description 19
150000003839 salts Chemical class 0.000 claims description 19
239000011248 coating agent Substances 0.000 claims description 16
239000007888 film coating Substances 0.000 claims description 16
238000009501 film coating Methods 0.000 claims description 16
229910052751 metal Inorganic materials 0.000 claims description 16
239000002184 metal Substances 0.000 claims description 16
239000004408 titanium dioxide Substances 0.000 claims description 16
150000002739 metals Chemical class 0.000 claims description 12
-1 yellow Inorganic materials 0.000 claims description 11
KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 claims description 10
229960003988 indigo carmine Drugs 0.000 claims description 10
239000004179 indigotine Substances 0.000 claims description 10
235000012738 indigotine Nutrition 0.000 claims description 10
239000004014 plasticizer Substances 0.000 claims description 9
239000000126 substance Substances 0.000 claims description 9
229920001223 polyethylene glycol Polymers 0.000 claims description 8
239000002202 Polyethylene glycol Substances 0.000 claims description 7
238000006731 degradation reaction Methods 0.000 claims description 7
ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims description 6
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 6
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 6
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 6
239000000654 additive Substances 0.000 claims description 5
239000006229 carbon black Substances 0.000 claims description 5
230000015556 catabolic process Effects 0.000 claims description 5
WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 claims description 5
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims description 5
239000001069 triethyl citrate Substances 0.000 claims description 5
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 4
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 4
235000013769 triethyl citrate Nutrition 0.000 claims description 4
MHVDTGCMSWKMPT-UHFFFAOYSA-N 3-acetyl-2-(3-acetyloxycarbonyl-2,4-dioxopentan-3-yl)-2-hydroxybutanedioic acid Chemical compound CC(=O)C(C(=O)O)C(C(=O)O)(C(C(=O)C)(C(=O)C)C(=O)OC(=O)C)O MHVDTGCMSWKMPT-UHFFFAOYSA-N 0.000 claims description 3
QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims description 3
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 3
239000001087 glyceryl triacetate Substances 0.000 claims description 3
235000013773 glyceryl triacetate Nutrition 0.000 claims description 3
239000008247 solid mixture Substances 0.000 claims description 3
229960002622 triacetin Drugs 0.000 claims description 3
235000013980 iron oxide Nutrition 0.000 abstract description 41
229960005191 ferric oxide Drugs 0.000 abstract description 38
239000003826 tablet Substances 0.000 description 49
239000000049 pigment Substances 0.000 description 17
239000000725 suspension Substances 0.000 description 15
229920000642 polymer Polymers 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
230000000694 effects Effects 0.000 description 9
239000008199 coating composition Substances 0.000 description 7
239000000454 talc Substances 0.000 description 7
235000012222 talc Nutrition 0.000 description 7
229910052623 talc Inorganic materials 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
239000000047 product Substances 0.000 description 6
229920002261 Corn starch Polymers 0.000 description 5
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
235000019359 magnesium stearate Nutrition 0.000 description 5
239000000463 material Substances 0.000 description 5
238000004806 packaging method and process Methods 0.000 description 5
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 4
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
235000019759 Maize starch Nutrition 0.000 description 4
229940081735 acetylcellulose Drugs 0.000 description 4
229920002301 cellulose acetate Polymers 0.000 description 4
239000003086 colorant Substances 0.000 description 4
239000012458 free base Substances 0.000 description 4
239000008187 granular material Substances 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
239000001863 hydroxypropyl cellulose Substances 0.000 description 4
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
229940071676 hydroxypropylcellulose Drugs 0.000 description 4
VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 4
238000000034 method Methods 0.000 description 4
239000000843 powder Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
229920002785 Croscarmellose sodium Polymers 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
229960001681 croscarmellose sodium Drugs 0.000 description 3
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
239000008380 degradant Substances 0.000 description 3
230000001627 detrimental effect Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
229940126534 drug product Drugs 0.000 description 3
238000001035 drying Methods 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
229960001021 lactose monohydrate Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 3
239000005022 packaging material Substances 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
239000007909 solid dosage form Substances 0.000 description 3
238000003860 storage Methods 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
229920003134 Eudragit® polymer Polymers 0.000 description 2
239000001828 Gelatine Substances 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229920003083 Kollidon® VA64 Polymers 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
235000011054 acetic acid Nutrition 0.000 description 2
230000000561 anti-psychotic effect Effects 0.000 description 2
239000002585 base Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
229940105329 carboxymethylcellulose Drugs 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229940081734 cellulose acetate phthalate Drugs 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000007799 cork Substances 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000007941 film coated tablet Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000002955 isolation Methods 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000002346 layers by function Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
229960002900 methylcellulose Drugs 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000010606 normalization Methods 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000002633 protecting effect Effects 0.000 description 2
239000008213 purified water Substances 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
238000009495 sugar coating Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
125000005591 trimellitate group Chemical group 0.000 description 2
239000001993 wax Substances 0.000 description 2
CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
244000024675 Eruca sativa Species 0.000 description 1
235000014755 Eruca sativa Nutrition 0.000 description 1
229920003153 Eudragit® NE polymer Polymers 0.000 description 1
229920003151 Eudragit® RL polymer Polymers 0.000 description 1
229920003152 Eudragit® RS polymer Polymers 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
239000008118 PEG 6000 Substances 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000011963 Substance-induced psychotic disease Diseases 0.000 description 1
231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 1
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
239000005030 aluminium foil Substances 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000003738 black carbon Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
229940105289 carbon black Drugs 0.000 description 1
235000019241 carbon black Nutrition 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
201000002545 drug psychosis Diseases 0.000 description 1
238000004049 embossing Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000013022 formulation composition Substances 0.000 description 1
238000004508 fractional distillation Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229960003943 hypromellose Drugs 0.000 description 1
238000005286 illumination Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000008188 pellet Substances 0.000 description 1
238000011170 pharmaceutical development Methods 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000012602 primary packaging material Substances 0.000 description 1
239000011253 protective coating Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
239000012603 secondary packaging material Substances 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000002356 single layer Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
229960005078 sorbitan sesquioleate Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000003068 static effect Effects 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000009662 stress testing Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
239000012463 white pigment Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002621866A 2005-09-08 2006-09-06 Stable solid formulation of sertindole Abandoned CA2621866A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA200501255		2005-09-08
DKPA200501255		2005-09-08
PCT/DK2006/050038 WO2007065448A1 (en)	2005-09-08	2006-09-06	Stable solid formulation of sertindole

Publications (1)

Publication Number	Publication Date
CA2621866A1 true CA2621866A1 (en)	2007-06-14

Family

ID=37697999

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002621866A Abandoned CA2621866A1 (en)	2005-09-08	2006-09-06	Stable solid formulation of sertindole

Country Status (17)

Country	Link
EP (1)	EP1924261A1 (pt)
JP (1)	JP2009507051A (pt)
KR (1)	KR20080042102A (pt)
CN (1)	CN101257906A (pt)
AR (1)	AR056475A1 (pt)
AU (1)	AU2006322460A1 (pt)
BR (1)	BRPI0615630A2 (pt)
CA (1)	CA2621866A1 (pt)
EA (1)	EA013167B1 (pt)
IL (1)	IL189541A0 (pt)
MX (1)	MX2008002290A (pt)
NO (1)	NO20081721L (pt)
NZ (1)	NZ565330A (pt)
TW (1)	TW200738239A (pt)
UA (1)	UA97349C2 (pt)
WO (1)	WO2007065448A1 (pt)
ZA (1)	ZA200801169B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI320783B (en)	2005-04-14	2010-02-21	Otsuka Pharma Co Ltd	Heterocyclic compound
WO2010087462A1 (ja) *	2009-01-29	2010-08-05	大日本住友製薬株式会社	内核を有する口腔内崩壊錠
FR2943061B1 (fr) *	2009-03-13	2011-02-25	Rhodia Operations	Composes organophosphores, systemes catalytiques comprenant ces composes et procede d'hydrocyanation ou d'hydroformylation utilisant ces systemes catalytiques
HUE057925T2 (hu)	2012-07-16	2022-06-28	Fibrogen Inc	Prolil hidroxiláz inhibitor kristályos alakjai
US8883823B2 (en)	2012-07-16	2014-11-11	Fibrogen, Inc.	Crystalline forms of a prolyl hydroxylase inhibitor
CA2914049C (en) *	2013-06-06	2021-10-12	Fibrogen, Inc.	Pharmaceutical formulations of a hif hydroxylase inhibitor
US10406103B2 (en)	2013-11-19	2019-09-10	Siga Technologies Inc.	Rehydration of micronized tecovirmimat monohydrate
JP2018172361A (ja) *	2016-10-14	2018-11-08	大原薬品工業株式会社	光安定性を改善した、デュロキセチンを含有する固形製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04346929A (ja) *	1991-05-22	1992-12-02	Takada Seiyaku Kk	光に安定なメシル酸ブロモクリプチン製剤
JP2000507544A (ja) *	1996-03-25	2000-06-20	イーライ・リリー・アンド・カンパニー	痛みの治療方法
ZA973433B (en) *	1996-04-24	1997-12-10	Shionogi & Co	A sertindole-containing preparation and a method for producing the same.
ZA977967B (en) *	1996-09-23	1999-03-04	Lilly Co Eli	Combination therapy for treatment of psychoses

2006
- 2006-06-09 UA UAA200803569A patent/UA97349C2/uk unknown
- 2006-08-17 TW TW095130202A patent/TW200738239A/zh unknown
- 2006-08-29 AR ARP060103764A patent/AR056475A1/es not_active Application Discontinuation
- 2006-09-06 WO PCT/DK2006/050038 patent/WO2007065448A1/en active Application Filing
- 2006-09-06 ZA ZA200801169A patent/ZA200801169B/xx unknown
- 2006-09-06 NZ NZ565330A patent/NZ565330A/en not_active IP Right Cessation
- 2006-09-06 EA EA200800774A patent/EA013167B1/ru not_active IP Right Cessation
- 2006-09-06 JP JP2008529472A patent/JP2009507051A/ja not_active Withdrawn
- 2006-09-06 CN CNA2006800323410A patent/CN101257906A/zh active Pending
- 2006-09-06 AU AU2006322460A patent/AU2006322460A1/en not_active Abandoned
- 2006-09-06 KR KR1020087004910A patent/KR20080042102A/ko not_active Application Discontinuation
- 2006-09-06 MX MX2008002290A patent/MX2008002290A/es not_active Application Discontinuation
- 2006-09-06 EP EP06846966A patent/EP1924261A1/en not_active Withdrawn
- 2006-09-06 CA CA002621866A patent/CA2621866A1/en not_active Abandoned
- 2006-09-06 BR BRPI0615630A patent/BRPI0615630A2/pt not_active IP Right Cessation
2008
- 2008-02-14 IL IL189541A patent/IL189541A0/en unknown
- 2008-04-08 NO NO20081721A patent/NO20081721L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN101257906A (zh)	2008-09-03
TW200738239A (en)	2007-10-16
WO2007065448A1 (en)	2007-06-14
IL189541A0 (en)	2008-08-07
ZA200801169B (en)	2010-07-28
EA013167B1 (ru)	2010-02-26
AU2006322460A1 (en)	2007-06-14
EP1924261A1 (en)	2008-05-28
UA97349C2 (uk)	2012-02-10
NO20081721L (no)	2008-04-08
KR20080042102A (ko)	2008-05-14
JP2009507051A (ja)	2009-02-19
BRPI0615630A2 (pt)	2016-11-16
MX2008002290A (es)	2008-03-14
NZ565330A (en)	2011-06-30
EA200800774A1 (ru)	2008-06-30
AR056475A1 (es)	2007-10-10

Publication	Publication Date	Title
TWI262079B (en)	2006-09-21	Controlled release Galantamine formulation
CA2621866A1 (en)	2007-06-14	Stable solid formulation of sertindole
CA2476054C (en)	2011-11-08	Pharmaceutical composition for the oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino)-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino)-propionic acid ethyl ester and the salts thereof
CA2819039C (en)	2018-09-11	Process for the preparation of a ppi-containing pharmaceutical product
US6537573B2 (en)	2003-03-25	Combination dosage form comprising cetirizine and pseudoephedrine
JP3665334B2 (ja)	2005-06-29	新規な医薬処方物
US20030181488A1 (en)	2003-09-25	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
WO2005092297A2 (en)	2005-10-06	A stable pharmaceutical composition comprising an acid labile drug
JP6364406B2 (ja)	2018-07-25	口腔内崩壊錠
JP2018177815A (ja)	2018-11-15	エスシタロプラム医薬組成物
EA030433B1 (ru)	2018-08-31	Энтеросолюбильная таблетка
HU228040B1 (en)	2012-09-28	Coated trimebutine maleate tablet
AU2005257977A1 (en)	2006-01-05	Stable pharmaceutical formulations of benzimidazole compounds
RU2593771C2 (ru)	2016-08-10	Энтеросолюбильная таблетка
CN110446707A (zh)	2019-11-12	药物制剂
EP2345408A2 (en)	2011-07-20	Acid labile drug formulations
US20070212412A1 (en)	2007-09-13	Stable solid formulation of sertindole
EP2293782A2 (en)	2011-03-16	Stable benzimidazole formulation
TW201832762A (zh)	2018-09-16	一種含有癒創木酚甘油醚的劑型組成及其應用
CN100431526C (zh)	2008-11-12	一种酸敏感型药物的快速崩解片剂
WO2003077829A2 (en)	2003-09-25	Process for preparation of a pharmaceutical composition containing acid labile compounds
WO2008062426A2 (en)	2008-05-29	Formulation of benzazepine derivatives
US20120082718A1 (en)	2012-04-05	Morphine Formulations
CN106668018B (zh)	2019-12-06	一种右兰索拉唑钠的缓释胶囊及其制备方法
JP2004231520A (ja)	2004-08-19	保存安定性及び溶出速度に優れた医薬組成物

Legal Events

Date	Code	Title	Description
2008-03-04	EEER	Examination request
2011-06-17	FZDE	Discontinued